- Home
- USEA vs KZIA Comparison
USEA vs KZIA Comparison
Compare USEA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- KZIA
- Stock Information
- Founded
- USEA 2004
- KZIA 1994
- Country
- USEA Greece
- KZIA Australia
- Employees
- USEA N/A
- KZIA N/A
- Industry
- USEA Marine Transportation
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- KZIA Health Care
- Exchange
- USEA Nasdaq
- KZIA Nasdaq
- Market Cap
- USEA 10.5M
- KZIA 9.0M
- IPO Year
- USEA N/A
- KZIA 1999
- Fundamental
- Price
- USEA $1.58
- KZIA $7.71
- Analyst Decision
- USEA
- KZIA Strong Buy
- Analyst Count
- USEA 0
- KZIA 2
- Target Price
- USEA N/A
- KZIA $14.00
- AVG Volume (30 Days)
- USEA 21.3K
- KZIA 67.0K
- Earning Date
- USEA 08-06-2025
- KZIA 09-02-2025
- Dividend Yield
- USEA 2.63%
- KZIA N/A
- EPS Growth
- USEA N/A
- KZIA N/A
- EPS
- USEA N/A
- KZIA N/A
- Revenue
- USEA $42,625,000.00
- KZIA $1,549,158.00
- Revenue This Year
- USEA N/A
- KZIA N/A
- Revenue Next Year
- USEA $11.62
- KZIA $49.25
- P/E Ratio
- USEA N/A
- KZIA N/A
- Revenue Growth
- USEA N/A
- KZIA 248983.08
- 52 Week Low
- USEA $1.00
- KZIA $2.86
- 52 Week High
- USEA $2.78
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- USEA 51.76
- KZIA 45.19
- Support Level
- USEA $1.50
- KZIA $6.22
- Resistance Level
- USEA $1.57
- KZIA $8.88
- Average True Range (ATR)
- USEA 0.07
- KZIA 0.60
- MACD
- USEA -0.01
- KZIA -0.15
- Stochastic Oscillator
- USEA 34.09
- KZIA 53.79
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.